Summary for 7QDL
| Entry DOI | 10.2210/pdb7qdl/pdb |
| Descriptor | Bromodomain-containing protein 4, (2S,4R)-1-acetyl-4-((5-chloropyrimidin-2-yl)amino)-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide, 1,2-ETHANEDIOL, ... (4 entities in total) |
| Functional Keywords | inhibitor, histone, epigenetic reader, bromodomain, brd4, bromodomain containing protein 4, antagonist, transcription |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 15645.39 |
| Authors | Chung, C. (deposition date: 2021-11-27, release date: 2022-12-14, Last modification date: 2024-05-01) |
| Primary citation | Humphreys, P.G.,Atkinson, S.J.,Bamborough, P.,Bit, R.A.,Chung, C.W.,Craggs, P.D.,Cutler, L.,Davis, R.,Ferrie, A.,Gong, G.,Gordon, L.J.,Gray, M.,Harrison, L.A.,Hayhow, T.G.,Haynes, A.,Henley, N.,Hirst, D.J.,Holyer, I.D.,Lindon, M.J.,Lovatt, C.,Lugo, D.,McCleary, S.,Molnar, J.,Osmani, Q.,Patten, C.,Preston, A.,Rioja, I.,Seal, J.T.,Smithers, N.,Sun, F.,Tang, D.,Taylor, S.,Theodoulou, N.H.,Thomas, C.,Watson, R.J.,Wellaway, C.R.,Zhu, L.,Tomkinson, N.C.O.,Prinjha, R.K. Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. J.Med.Chem., 65:2262-2287, 2022 Cited by PubMed Abstract: Through regulation of the epigenome, the bromodomain and extra terminal (BET) family of proteins represent important therapeutic targets for the treatment of human disease. Through mimicking the endogenous -acetyl-lysine group and disrupting the protein-protein interaction between histone tails and the bromodomain, several small molecule pan-BET inhibitors have progressed to oncology clinical trials. This work describes the medicinal chemistry strategy and execution to deliver an orally bioavailable tetrahydroquinoline (THQ) pan-BET candidate. Critical to the success of this endeavor was a potency agnostic analysis of a data set of 1999 THQ BET inhibitors within the GSK collection which enabled identification of appropriate lipophilicity space to deliver compounds with a higher probability of desired oral candidate quality properties. SAR knowledge was leveraged via Free-Wilson analysis within this design space to identify a small group of targets which ultimately delivered I-BET567 (), a pan-BET candidate inhibitor that demonstrated efficacy in mouse models of oncology and inflammation. PubMed: 34995458DOI: 10.1021/acs.jmedchem.1c01747 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.67 Å) |
Structure validation
Download full validation report
